Boehringer Ingelheim Tipranavir NDA Could Signal Novel HIV Salvage Option

Non-peptidic protease inhibitor is “potent new treatment” for multi-drug-resistant HIV strains, firm says. NDA seeks accelerated approval and priority review for treatment of HIV-1 in combination with antiretrovirals in PI-experienced patients.